Detroit Free Press

NanoViricides Dual Track Clinical Strategy Explained by a Research Report – Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...
Morningstar

Volastra Therapeutics Expands Clinical Development Program Following Encouraging KIF18A Inhibitor Data and Appoints New Chief Medical Officer to Lead Clinical Strategy

Company reports encouraging monotherapy expansion data in platinum-resistant ovarian cancer and initiates first combination study with standard-of-care chemotherapies in Q1 2026 Timothy Bowler, M.D., ...

Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical development strategy includes an mCRPC-dedicated Phase 1b trial in PLUVICTO®-naïve and -experienced patients, and a ...
Seeking Alpha

Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate

AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio’s purpose-built agentic AI platform for the biotechnology industry TORONTO ...

Immunic appoints new medical officer to lead clinical and regulatory strategy

Immunic Inc. IMUX on Tuesday announced it appointed Michael Panzara as its Chief Medical Officer, effective April 24, 2026, as the company looks to advance its clinical and regulatory strategy. The ...